[文章] 依非诺肽治疗代谢功能障碍相关脂肪性肝炎伴2–3期纤维化成人的疗效与安全性:一项2b期、随机、安慰剂对照研究
完整摘要 · 中文译文
背景:Efinopegdutide是一种药理学上独特的每周一次GLP-1-胰高血糖素受体共激动剂,其相对受体效力平衡约为2:1,正在开发用于代谢功能障碍相关脂肪性肝炎(MASH)。我们旨在研究efinopegdutide在非肝硬化MASH成人中的疗效和安全性。 方法:我们在26个国家的176个学术和社区中心开展了一项2b期、随机、安慰剂对照、双盲研究。我们纳入年龄≥18岁、经活检确诊为MASH且纤维化为2期或3期的成人。符合条件的参与者被随机分配(1:1:1:1:1)接受efinopegdutide(4 mg、7 mg或10 mg)、安慰剂或开放标签司美格鲁肽2·4 mg,均每周皮下给药一次。随机化在中枢进行。主要终点为第52周时MASH缓解且纤维化未恶化。关键次要组织学终点为纤维化改善至少一个分期且脂肪性肝炎未恶化。治疗结束时缺失的活检在主要分析中被视为失败。本研究已在EU CT注册,注册号2022-502647-35-00,并在ClinicalTrials.gov注册,注册号NCT05877547,研究已完成。 研究结果:2023年6月23日至2025年12月29日期间,我们筛选了1704名参与者。我们随机分配了386名(23%)参与者,其中381名(99%;194名[51%]女性,187名[49%]男性)接受了至少一剂研究干预并纳入分析。各组基线特征相似;381名参与者中239名(63%)有F2期纤维化,142名(37%)有F3期纤维化;参与者平均年龄为53岁(SD 13)。第52周时,在不伴纤维化恶化的情况下实现MASH缓解的参与者分别为:efinopegdutide 4 mg组55名参与者中的31名(56%)、efinopegdutide 7 mg组49名参与者中的31名(63%)、efinopegdutide 10 mg组57名参与者中的35名(61%),而安慰剂组为53名参与者中的7名(13%)(与安慰剂的差异:4 mg组为43.0个百分点[95% CI 25.7至57.8;p<0.0001],7 mg组为49.5个百分点[31.4至64.2;p<0.0001],10 mg组为47.8个百分点[30.7至62.0;p<0.0001]);接受semaglutide的49名参与者中有26名(53%)达到该终点。对于关键次要终点,在不伴脂肪性肝炎恶化的情况下实现至少一个阶段的纤维化改善的参与者分别为:efinopegdutide 4 mg组75名参与者中的32名(43%)、efinopegdutide 7 mg组75名参与者中的39名(52%)、efinopegdutide 10 mg组77名参与者中的26名(34%),而接受安慰剂的77名参与者中为16名(21%)(与安慰剂的差异:efinopegdutide 4 mg组为21.7个百分点[7.1至35.7;p=0.0038],efinopegdutide 7 mg组为30.4个百分点[15.4至44.3;p<0.0001],以及 efinopegdutide 10 mg组为13·0个百分点[-1·2至26·8;p=0·072]);接受司美格鲁肽的65名参与者中有16名(25%)达到该终点。efinopegdutide最常见的不良事件为胃肠道不良事件,其中efinopegdutide 10 mg组参与者的发生率最高。导致停止研究干预的不良事件在efinopegdutide 10 mg组参与者中发生更频繁(79名参与者中9名[11%]),而其他efinopegdutide剂量组(范围3-4%)或安慰剂组(1名[1%])较低。 解释:与安慰剂相比,接受efinopegdutide治疗可使显著更高比例的参与者实现MASH消退且纤维化未加重。7 mg剂量显示出最有利的获益-风险特征,在治疗1年后约半数参与者中使纤维化至少改善一个分期且脂肪性肝炎未加重。这些发现支持efinopegdutide作为一种每周一次的GLP-1-胰高血糖素受体共激动剂在MASH中的潜在应用价值。 资助:Merck Sharp & Dohme,Merck & Co.的子公司。
完整摘要 · 英文原文
BACKGROUND: Efinopegdutide is a pharmacologically distinct once-weekly GLP-1-glucagon receptor co-agonist with a relative receptor potency balance of approximately 2:1 under development for metabolic dysfunction-associated steatohepatitis (MASH). We aimed to investigate the efficacy and safety of efinopegdutide in adults with non-cirrhotic MASH. METHODS: We did a phase 2b, randomised, placebo-controlled, double-blind study conducted at 176 academic and community centres in 26 countries. We included adults (aged ≥18 years) with biopsy-confirmed MASH and stage 2 or stage 3 fibrosis. Eligible participants were randomly assigned (1:1:1:1:1) to receive either efinopegdutide (4 mg, 7 mg, or 10 mg), placebo, or open-label semaglutide 2·4 mg, all administered subcutaneously once weekly. Randomisation was performed centrally. The primary endpoint was MASH resolution without worsening of fibrosis at week 52. The key secondary histological endpoint was fibrosis improvement of at least one stage without worsening of steatohepatitis. Missing end-of-treatment biopsies were considered as failure for the primary analysis. This study is registered with EU CT, 2022-502647-35-00, and ClinicalTrials.gov, NCT05877547, and is complete. FINDINGS: Between June 23, 2023, and Dec 29, 2025, we screened 1704 participants. We randomly assigned 386 (23%) participants, of whom 381 (99%; 194 [51%] women and 187 [49%] men) received at least one dose of study intervention and were included in the analysis. Baseline characteristics were similar across groups; 239 (63%) of 381 participants had F2 fibrosis and 142 (37%) had F3 fibrosis; the mean age of participants was 53 years (SD 13). At week 52, MASH resolution without worsening of fibrosis occurred in 31 (56%) of 55 participants in the 4 mg efinopegdutide group, 31 (63%) of 49 participants in the 7 mg efinopegdutide group, and 35 (61%) of 57 participants in the 10 mg efinopegdutide group versus seven (13%) of 53 participants in the placebo group (difference vs placebo 43·0 percentage points [95% CI 25·7 to 57·8; p<0·0001] for 4 mg, 49·5 percentage points [31·4 to 64·2; p<0·0001] for 7 mg, and 47·8 percentage points [30·7 to 62·0; p<0·0001] for 10 mg); 26 (53%) of 49 participants receiving semaglutide met this endpoint. For the key secondary endpoint, fibrosis improvement of at least one stage without worsening of steatohepatitis occurred in 32 (43%) of 75 participants in the efinopegdutide 4 mg group, 39 (52%) of 75 participants in the 7 mg efinopegdutide group, and 26 (34%) of 77 participants in the efinopegdutide 10 mg group versus 16 (21%) of 77 participants receiving placebo (difference vs placebo 21·7 percentage points [7·1 to 35·7; p=0·0038] in the efinopegdutide 4 mg group, 30·4 percentage points [15·4 to 44·3; p<0·0001] in the efinopegdutide 7 mg group, and 13·0 percentage points [-1·2 to 26·8; p=0·072] in the efinopegdutide 10 mg group); 16 (25%) of 65 participants receiving semaglutide met this endpoint. The most frequently reported adverse events with efinopegdutide were gastrointestinal, with the highest rates among participants receiving efinopegdutide 10 mg. Adverse events leading to discontinuation of study intervention occurred more frequently among participants receiving efinopegdutide 10 mg (nine [11%] of 79 participants) compared with the other doses of efinopegdutide (range 3-4%) or placebo (one [1%]). INTERPRETATION: Treatment with efinopegdutide resulted in a significantly greater proportion of participants with MASH resolution without worsening of fibrosis compared with placebo. The 7 mg dose showed the most favourable benefit-risk profile, improving fibrosis by at least one stage without worsening steatohepatitis in approximately half of participants after 1 year of treatment. These findings support the potential utility of efinopegdutide as a once-weekly GLP-1-glucagon receptor co-agonist in MASH. FUNDING: Merck Sharp & Dohme, a subsidiary of Merck & Co.